BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 25, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 1/22 cls
China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) Jefferies Marko Kozul New Buy -11% $7.98
Kozul set a $13 target. He expect the shares to be driven by sales updates for its approved drugs, as the company expands its sales and market distribution in China. Key approved products include Baquting hemocoagulase to treat and prevent bleeding; and Kaitong, an injectable lipid emulsion of alprostadil to treat peripheral vascular disease. China Nuokang raised $40.7M in an IPO in December (see...

Read the full 581 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >